UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934



Date of Report (date of earliest event reported): May 4, 2018


Commission File No. 001-12575


UTAH MEDICAL PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)


UTAH
87‑0342734
(State or other jurisdiction of incorporation or organization)
 (I.R.S. Employer Identification No.)


7043 South 300 West
Midvale, Utah  84047
Address of principal executive offices


Registrant's telephone number:     (801) 566‑1200

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


On May 4, 2018 at the annual meeting, stockholders of the Company approved or indicated their preference on the following matters submitted to them for consideration:

Elected Kevin L. Cornwell as a director of the Company:
 
For
1,968,641
Withheld
944,174
Broker Non Votes
554,710

Elected Paul O. Richins as a director of the Company:
 
For
1,629,745
Withheld
1,283,070
Broker Non Votes
554,710

Ratified the selection of Jones Simkins LLC as the Company's independent public accounting firm for the year ended December 31, 2018:
 
For
2,749,342
Against
405,501
Abstentions
312,682
 
Approved, on an advisory basis, the compensation paid to UTMD's named executive officers, including the Compensation Discussion and Analysis, compensation tables and narrative discussion:
 
For
2,793,234
Against 
 111,653
Abstentions
7,928
Broker Non Votes
554,710

Indicated, on a non-binding basis, preference for replacing plurality voting for uncontested board seats with a majority voting standard:
 
For
2,334,113
Against
563,807
Abstentions
14,895
Broker Non Votes
554,710

The Company will include annual advisory stockholder votes on executive compensation in its proxy materials.  Annual advisory stockholder votes will be held until at least the next required advisory vote on frequency of stockholder votes on the compensation of executives.

The Company's Board of Directors will take a deliberate approach to considering what is in the best interest of all stockholders regarding changing the voting standard for uncontested board seats.



SIGNATURES


Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
UTAH MEDICAL PRODUCTS, INC.
 
REGISTRANT
   
   
Date: 5/08/2018
 By: /s/ Kevin L. Cornwell
 
Kevin L. Cornwell
 
CEO